Introduction
============

Nasopharyngeal carcinoma (NPC) is one type of malignancies with obvious regional differences [@B1], [@B2]. In China, the morbidity of NPC is higher in southern region, especially in the eastern part of Guangzhou and Guangxi, and the incidence rate is about 25-50/100000 [@B3]. The development and progression of NPC is a complicated process induced by multi-factors. It may be caused by EB virus infection [@B4], [@B5], environmental and dietary factors [@B6], genetic susceptibility [@B7], [@B8], and chronic inflammation [@B9]. Until now, it is still unclear about the molecular mechanisms of NPC.

Long palate, lung and nasal epithelium clone 1 (LPLUNC1) belongs to PLUNC family, which is also named BPI fold containing family B, member 1 (BPIFB1) [@B10]. LPLUNC1 gene encodes 484 amino acids and contains 2 BPI structural domain, which is a new member in BPI/PLUNC super family [@B11]. It was studied that LPLUNC1 expression showed tissue specificity in nasopharyngeal [@B12]. In our previous study, we found that LPLUNC1 was down-regulated in NPC tissues, which might play as a potential tumor suppressor gene [@B13]. Over-expressed LPLUNC1 can repress proliferation of NPC cells, arrest the cells in G0/G1 stage, and induce cell apoptosis [@B14], [@B15]. LPLUNC1 protein can inhibit proliferation of NPC cells induced by IL-6 through suppressing STAT3 signaling pathway [@B14]. Actually, the molecular mechanism of LPLUNC1 in NPC development is still unclear. To further investigate the roles and mechanisms of LPLUNC1 in NPC, we applied two-dimensional fluorescence difference gel electrophoresis (2-D DIGE) and matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-TOF-MS/MS) to analyze the changes of proteomics profiles after LPLUNC1 over-expression. It is necessary to identify down-stream genes regulated by LPLUNC1, which provides more valuable indications to understand LPLUNC1 function.

Hypoxia up-regulated 1 protein, also known as oxygen-regulated protein 150 (ORP150), is encoded by HYOU1 gene, which belongs to heat shock protein 70 (HSP70) family. Studies showed that ORP150 protein was over-expressed in many tumors, which was closely related to tumor invasion [@B16]-[@B18]. Increasing of ORP150 protein was correlated with poor prognosis [@B16], and highly expressed ORP150 inhibited apoptosis of tumor cells induced by drugs [@B15], [@B16]. However, the relationship between HYOU1 and cancer requires further investigation in NPC.

In this study, we applied proteomics technology to identify differentially expressed proteins in NPC cells after LPLUNC1 over-expression. The up-regulated 19 proteins and down-regulated 25 proteins were mainly involved in the biological processes including cell metabolism, proliferation, transcription, and signaling transduction, which provided more valuable clues to understand the roles of LPLUNC1 in NPC. HYOU1 was found to be regulated by LPLUNC1 as it was differentially expressed between over-expressed LPLUNC1 NPC cells and NPC cells. Subsequently, HYOU1 is identified to be significantly increased in NPC tissues, which may be regarded as a potential biomarker of malignant progression and poor prognosis in NPC.

Materials and Methods
=====================

Establishment of stably LPLUNC1-expressing NPC cells
----------------------------------------------------

The NPC cell lines including 5-8F, HNE2 and HONE1 were reserved by Cancer Research Institute of Central South University. After thawing, the cell lines were cultured in RPMI1640 medium containing 10% FBS in the environment of 95% humidity, 5% CO~2~ at 37 °C. The stably LPLUNC1-expressing NPC cells were established as our previous studies [@B11], [@B25]. Briefly, 5-8F, HNE2, HONE1 cells at 4×10^5^/ml were cultured overnight and transfected with vector pIRESneo3 (Clontech, USA) or pIRESneo3-LPLUNC1 (containing a full-length LPLUNC1 cDNA) using Lipofectamine 2000 according to the manufacturer\'s instruction (Invitrogen, USA). Subsequently, the cells were treated 1 mg/ml of G418 for the selection of positive clones. The LPLUNC1 expression in G418-resistant cells was characterized by quantitative real-time PCR and Western blot. Cell lines stably over-expressing LULUNC1 and cell lines with blank vector were labelled as 5-8F/LPLUNC1 and 5-8F/Vector, HNE2/LPLUNC1 and HNE2/Vector, HONE1/LPLUNC1 and HNOE1/Vector.

Collection of tumor samples
---------------------------

For preparing the NPC tissue microarray (TMA) to detect the protein expression by immunohistochemistry (IHC), we used 387 patients with NPC (256 cases) and non-tumor nasopharyngeal epithelium (NPE, 131 cases) from the Ear, Nose and Throat (ENT) department at Xiangya Hospital and the Second Xiangya Hospital (Changsha, PR China) during January 2002 to October 2004 to collect NPC tumor tissues. The clinicopathologic characteristics of these subjects were listed in Table [1](#T1){ref-type="table"}. Among all of the NPC patients, we followed up 81 patients to do survival analysis. The time of following up was from 4 to 95 month, and average was 57 month. All biopsies were immediately fixed in 4% buffered paraformaldehyde, then routinely processed and embedded in paraffin.

For the mRNA expression study, 36 NPC tissues and 15 NPE samples were obtained from patients in the Hunan Cancer Hospital (the Affiliated Cancer Hospital of Xiangya School Of Medicine, Changsha, China) in 2013. All tissue samples were quick frozen in liquid nitrogen and stored at -80°C until laser-capture micro-dissection (LCM). We used a LEICA CM 1900 (Leica, Solms, Germany) for frozen sections and the Leica AS LMD system (Leica) to obtain the pure tissues.

All of the individuals participating in this project signed the informed consent form and their name, sex, age, pathological diagnosis, tumor, nodal status, metastasis and tumor-node-metastasis classification were recorded.

Two-dimensional fluorescence difference gel electrophoresis (2-D DIGE)
----------------------------------------------------------------------

The LPLUNC1-induced differentially expressed protein profile in NPC cells was characterized by 2-D DIGE analysis as described in our previous study [@B19]. Briefly, cells were collected after growth about 80% fusion, then 2-D DIGE lysate (30mM Tris-HCl, 2M Thiourea, 7M Urea, 4% CHAPS, pH 8.5 protease inhibitor cocktail) was added. Total proteins were extracted on ice, and then the impurities were removed based on the standard protocol of 2D clean-up kit (Bio-Rad, Hercules, California, USA). The BCA assay (Pierce, Beijing, China) was used to detect the protein concentration. Proteins were labelled with fluorescent dye Cy2, Cy3, and Cy5 respectively following the standard procedure of DIGETM kit (GE Healthcare, Piscataway, New Jersey, USA). The protein lysates were subjected to fluorescence dye labeling at a dye/protein ratio of 400 pmol/100 µg for 30 min. Then, 20 µg of proteins from each group were mixed with the same volume of DIGE 2×buffer (8 mol/l urea, 4% w/v CHAPS, 2% w/v DTT, 2% v/v pharmalytes, pH 3-10 for IEF). In addition, 20µg of individual samples were diluted in the rehydration solution (8 mol/l urea, 0.5% w/v CHAPS, 0.2% w/v DTT, 0.2% v/v pharmalyte, pH 3-10). Samples were loaded onto IPG strips (18 cm, pH 3-10, nonlinear, GE Healthcare, Piscataway, New Jersey, USA) for 2-D gel electrophoresis. Fluorescence images were acquired using the Ettan DIGE imager (GE Healthcare, Piscataway, New Jersey, USA), and DIGE gels were analyzed using the DIA (differential in-gel analysis) module of the DeCyder software (version 6.5; GE Healthcare, Piscataway, New Jersey, USA).The differentially expressed proteins were identified by comparing the relative expression (Cy3/Cy2 or Cy5/Cy2) based on the rules (\|ratio≥1.2\|, P≤0.05) after matching each spot. At the same time, to prepare gels to capture the spots of interest, 1000µg of protein was subjected to 2-D DIGE on IPG strips and stained with Coomassie brilliant blue.

Mass spectrometric analysis and protein identification
------------------------------------------------------

The protein spots of interest were excised and de-stained with 25 mmol/l ammonium bicarbonate/50% acetonitrile (CAN), and in-gel digestion was performed with 0.01 µg/µl trypsin (Promega, Madison, Wisconsin, USA) in 25 mmol/l ammonium bicarbonate for 15 h at 37°C. The hydrolysates were collected, and the tryptic peptides were extracted from the gel pieces sequentially with 5% TFA at 40°C for 1 h and then 2.5% TFA/50% ACN at 30°C for 1 h. The extracts were pooled, lyophilized and stored at -20°C until use. Gel pieces from a \'blank\' region and from the BSA molecular mass marker were used as negative and positive controls, respectively.

Subsequently, the peptide mixtures were re-dissolved in 0.5% TFA, and 1 µl of peptide solution was mixed with an equal volume of matrix (4-hydroxy-a-cyanocinnamic acid in 30% ACN/ 0.1% TFA). Then, the peptides were spotted on the target plate. Individual protein peptides were identified by MALDI-TOF-TOF mass spectrometry on a 4700 Proteomics Analyser (Applied Biosystems, Foster City, California, USA). The mass spectra were used to examine human protein sequences in the Swiss-Prot database using the Mascot database search algorithm (version 1.9).

RNA isolation and qRT-PCR
-------------------------

Total RNA was extracted from NPC and NPE tissues using the Trizol extraction kit (Invitrogen) according to the manufacturer\'s instructions, and then reversely transcribed into cDNA using AMV reverse transcriptase (Promega, San Luis Obispo, CA, USA). The levels of target gene mRNA transcripts were determined by qRT-PCR using specific primers and a SYBR-green-containing PCR kit (GenePharma, Shanghai, China). The sequences of primers were forward 5\'-CTTCCACATCAACTACGGCG-3\' and reverse 5\'-CTCTTCTGCGCTGTCCTCTA-3\' for HYOU1 (235 bp); forward 5\'-GAAGGTGAAGGTCGGAGTC-3\' and reverse 5\'-GAAGATGGTGATGGGATTTC-3\' for GAPDH (226 bp). The relative levels of individual gene mRNA transcripts to control GAPDH were determined.

Western blotting
----------------

Total protein was extracted from NPC cells, and the levels of targeting proteins were determined by western blot assays using primary antibodies, including anti-HYOU1 (Abnova, Taibei, Taiwan) and anti-β-actin (Boster, Wuhan, China). The bound antibodies were detected by horseradish peroxidase-conjugated second antibodies and visualized using ECL (Pierce, Rockford, IL, USA). The relative levels of individual proteins to control β-actin were analyzed by ImagJ2 software (Madison, WI, USA).

Immunohistochemistry (IHC)
--------------------------

The expression of HYOU1 in individual NPC and non-tumor NPE specimens was characterized by IHC using the standard streptavidin/peroxidase staining method. For immunohistochemical staining, individual tissue sections at 4 uM were stained with polyclonal mouse anti-HYOU1 (1:500, Abnova, Taibei, Taiwan). Negative mouse serum was used instead of the primary antibody as negative control. A semi-quantitative scoring criterion for IHC was used in which the staining intensity and positive areas were recorded as previously described [@B20]. The intensity of anti-HYOU1 staining was scored by 0-3, according to the standards of 0 (no staining), 1 (weak staining), 2 (moderate staining) and 3 (strong staining). The percentage of the extent of reactivity was scored as follows: 0 (no positive tumor cells), 1 (\<10% positive tumor cells), 2 (10-50% positive tumor cells) and 3 (\>50% positive tumor cells). Next, the expression score was obtained by multiplying the intensity and reactivity rate values. Scores of \< 4 were classified as low expression, and the remainders were classified as high expression. Individual samples were evaluated by at least two pathologists in a blinded manner, and those samples with inconsistent scores were further discussed and decided.

Statistical analysis
--------------------

All analyses were performed using SPSS 15.0 program for Windows software package (SPSS, Chicago, IL, USA). Statistical significance among groups was determined by the One-way ANOVA and Student t-test. The chi-square test was used to determine whether two groups had distinct gene expression levels. Survival was estimated using the Kaplan-Meier method and compared by log-rank test. Multivariate logistic analyses using a stepwise Cox regression model after adjusting for baseline characteristics. A P-value of \< 0.05 was considered statistically significant.

Results
=======

Differential analysis of protein profiles
-----------------------------------------

To identify the differentially expressed protein profiles between cells with LPLUNC1 overexpression and cells with LPLUNC1 normal expression, we isolated total proteins in 5-8F/LPLUNC1 and 5-8F/Vector by 2-D DIGE method. After Cy2, Cy3 and Cy5 three-channel image scanning, DeCyder 6.5 software was applied to analyze the matched points in different gel by the rules (t-test, P \< 0.05), as shown in Fig. [1](#F1){ref-type="fig"}A. It was found that 52 proteins were selected as differentially expressed at fold change of 1.2, among which 23 proteins were up-regulated and 29 were down-regulated. Fig. [1](#F1){ref-type="fig"}B showed the 3D simulation and curves of point 454, and the expression were significantly decreased after LPLUNC1 over-expression (P = 0.00067). The results indicated that over-expressed LPLUNC1 can induce changes of proteomics profiles in NPC.

Identification of differentially expressed proteins and functional classification
---------------------------------------------------------------------------------

To identify above differentially expressed proteins, we applied mass spectrometry technology to compare the characters with known proteins. After cutting and in-gel digestion, we used MALDI-TOF/TOF-MS/MS to get peptide mass fingerprinting (PMF), and Mascot Distiller software was applied to calculate mass load ratio (m/z) values of peptide fragment through analyzing single isotope PMF. Through searching Mascot query system, SWISS-PROT and NCBInr protein databases, we identified the corresponding proteins. The PMF signals of 454 were shown in Fig. [2](#F2){ref-type="fig"}A, and the analyzed and searched results were shown in Fig. [2](#F2){ref-type="fig"}B. The corresponding protein included Hypoxia up-regulated 1 protein (HYOU1). In this study, we identified 44 proteins in 52 differentially expressed proteins, among which 19 proteins were up-regulated and 25 proteins were down-regulated, as shown in Table [2](#T2){ref-type="table"}. Based on functional annotation in SWISS-PORT and NCBInr database, these differentially expressed proteins can be classified into five classes: (1) chaperone protein; (2) the cytoskeletal protein; (3) cell metabolism enzymes or proteins; (4) signal transduction molecules; (5) Other functional proteins. The results indicated that LPLUNC1 regulated the growth of NPC through participating in processes of cell metabolism, proliferation, transcription and signaling transduction.

Validation of HYOU1
-------------------

To validate the results from proteomics analysis, we selected HYOU1 for further validation by qRT-PCR and Western blot. It was shown that the expressions of HYOU1 was significantly down-regulated after over-expressing LPLUNC1 in 5-8F cell lines, which was consistent with mass spectrometry results (as shown in Fig. [3](#F3){ref-type="fig"}A). As shown in Fig. [3](#F3){ref-type="fig"}B and [3](#F3){ref-type="fig"}C, the expression of HYOU1 was also significantly down-regulated after over-expressing LPLUNC1 in HNE2 and HONE1 cells. All the results indicated that the identification based on proteomics was accurate and reliable.

Expression of HYOU1 in NPC tissues
----------------------------------

To further investigate the expressions and clinical associations of HYOU1 protein in NPC tissues, we applied NPC tissue microarray and IHC methods to detect the expressions. It was found that the expressions of HYOU1 protein significantly increased in NPC tissues than in normal nasopharyngeal epithelium (X^2^ =84.041, P = 0.000). As shown in Table [3](#T3){ref-type="table"}, HYOU1 protein expression (171/256, 66.80%) was higher in NPC tissues, but only 23 out of 131 NPE specimens (17.56%) had a high expression of HYOU1. HYOU1 protein expression was positively correlated with clinical staging (P \< 0.001) and metastasis (P = 0.004), while no significant association with gender (P = 0.405) and age (P = 0.583) was found. Fig. [4](#F4){ref-type="fig"}A showed a typical expression of HYOU1 protein in NPC tissues. We also applied laser capture microdissection (LCM) to ensure the purity of NPC tissues and normal nasopharyngeal tissues. We applied qRT-PCR to further detect expression of HYOU1 in mRNA level. It was shown that HYOU1 mRNA expression was also up-regulated significantly in NPC tissues (P \< 0.001, as shown in Fig. [4](#F4){ref-type="fig"}B). All these results illustrated that high expression of HYOU1 may promote the development and progression of NPC.

Association of poor prognosis with expression of HYOU1
------------------------------------------------------

To understand the relationship of prognosis with expression of HYOU1 in NPC, we applied Kaplan-Meier method to do survival analysis for 81 patients (follow up from 4 to 95 months, average 57 months). As shown in Fig. [5](#F5){ref-type="fig"}, HYOU1 protein expression was closely related to overall survival (OS) and progression free survival (PFS). PFS (36.8% vs 69.8%, X^2^ =13.618, P \< 0.001) and OS (36.8% vs 69.8%, X^2^ =15.660, P \< 0.001) in NPC patients with low expression of HYOU1 protein was significantly better than patients with high expression. As shown in Table [4](#T4){ref-type="table"}, we found that the age, gender, clinical staging and metastasis had no significant association with PFS or OS of patients through COX multi-factor regression, while HYOU1 protein expression was significantly related to the PFS and OS. For example, NPC patients who had high expression of HYOU1 protein, had a shorter PFS and OS. PFS HR was 2.602 (P = 0.007), and OS HR was 2.507 (P = 0.010). In summary, we can conclude that highly expressed HYOU1 is a potential biomarker of poor prognosis in NPC patients.

Discussion
==========

As the traditional two-dimensional gel electrophoresis runs on different gels, the difference between gels is difficult to distinguish system error with sample difference, which limits its application. 2D-DIGE can isolate and analyze multiple samples on same piece of gel to eliminate systematic errors, which is particularly suitable in proteomics difference research. At the same time, 2D-DIGE technology adds a third fluorescent color as an internal standard, which can effectively reduce the system error and greatly improve the accuracy, reliability and reproducibility of quantitative results [@B21]. In this study, we obtained differentially expressed protein profiles by 2-D DIGE and MALDI-TOF/TOF-MS mass spectrometry technologies in NPC 5-8F cells before and after LPLUNC1 over-expression. Western blot and qRT-PCR were also applied to validate some differential proteins in mRNA level and protein level. The results were fully consistent with mass spectrometry, which indicated the accuracy and reliability of proteomics analysis.

In current study, 44 differentially expressed proteins were identified between 5-8F/LPLUNC1 and 5-8F/Vector NPC cells, which were mainly involved in molecular chaperone, cytoskeleton, metabolism and signal transduction. Among the identified proteins, stratifin (14-3-3σ), annexin I (ANXA1) and prohibitin that were frequently identified in quantitative proteomics were demonstrated to be associated with the progression of NPC [@B22], and may be regarded as the potential biomarkers of NPC [@B22], [@B23]. Stratifin, annexin I and prohibitin were significantly decreased in NPC, which were associated with the poor survival of NPC patients [@B19], [@B24], [@B25]. Up-regulated stratifin and annexin I can significantly suppress the capabilities of cell proliferation, adhesion, migration, and invasion in NPC cells, which also enhanced the radiosensitiza tion of NPC cells [@B26]-[@B28]. In addition, numerous studies have shown that stratifin, annexin I and prohibitin are aberrantly expressed in a wide spectrum of tumors, and their abnormal expressions play a crucial role in tumor growth and progression [@B23], [@B29], [@B30]. In our study, stratifin and annexin I and prohibitin were up-regulated by LPLUNC1, which might be involved in the inhibitory roles of LPLUNC1 in NPC. However, the possible mechanisms and intrinsic relationships of them should be further elucidated in NPC.

HYOU1 was identified as differentially expressed genes in NPC cells after overexpressing LPLUNC1 by proteomic techniques. It was studied that LPLUNC1 was highly expressed with nasopharyngeal tissue specificity [@B12]. In our previous study, we found that LPLUNC1 was down-regulated in NPC tissues, which might play as a potential tumor suppressor gene [@B13]. Over-expressed LPLUNC1 can repress proliferation of NPC cells, arrest the cells in G0/G1 stage, and induce cell apoptosis [@B14], [@B15]. This suggests that LPLUNC1 can inhibit the growth of NPC cells through regulating protein expressions of HYOU1. It is also shows HYOU1 may play important roles in the development of NPC.

HYOU1 protein is known as oxygen-regulated protein 150 (ORP150). Under hypoxia, ORP150 protein can be accumulated in the endoplasmic reticulum to protect cells from hypoxia interference, while inhibition of ORP150 expression can accelerate cell apoptosis [@B31]. It is reported that ORP150 protein was up-regulated in prostate cancer [@B32], bladder cancer [@B33] and breast cancer [@B16], colorectal cancer [@B17] and other tumors[@B34], and high expression of ORP150 was positively correlated with high invasion and poor diagnosis[@B18]. Over-expressed ORP150 protein can significantly inhibit the tumor cell apoptosis induced by anti-tumor drugs [@B31], [@B35], and promote the resistance of tumor cells to chemotherapy [@B21]. Decreased expression of HYOU1 can significantly inhibit proliferation of tumor cells and postpone tumor progression [@B32]. However, considering the current evidence, the role of HYOU1 expression in different tumors is unclear, also is unclear in NPC patients. In this study, we examined the relationship between alterations in HYOU1 expression and the prognosis of patients with NPC.

We found that the expression of HYOU1 was significantly increased in NPC tissues either in protein level or mRNA level, which positively correlated with the clinical stage and metastasis in NPC. The results suggested that HYOU1 played important roles in development and progression of NPC. Survival analysis showed over-expressed HYOU1 in NPC patients had poor prognosis, with a shorter PFS and OS. COX multivariate regression analysis showed high expressions of HYOU1 protein is an important biomarker associated with poor prognosis in NPC patients.

In summary, applying quantitative proteomics analysis, 44 differentially expressed proteins were identified to be regulated by LPLUNC1, among which 19 were up-regulated and 35 were down-regulated. Through regulating these differentially expressed proteins, LPLUNC1 may regulate the growth of NPC through participating in cell metabolism, proliferation, transcription and signal transduction , which provides valuable clues for further study of LPLUNC1 function. Based on further investigation, we found that HYOU1 was significantly up-regulated in NPC tissues. HYOU1 may be regarded as biomarkers of malignant progression and poor prognosis, even potential novel targets for diagnosis and treatment of NPC. However, the function of HYOU1 in NPC need to be further elucidated *in vivo* and *in vitro*.
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![Comparative proteomic analyses of the 5-8F/LPLUNC1 (long palate, lung, nasal epithelium clone 1) and 5-8F/Vector using two-dimensional fluorescence difference gel electrophoresis (2D-DIGE). A) 2D-DIGE gel images, and differential protein spots detected by Decyder software. The pI ranges from 4 to 7 (left to right). B) Spot 454 three-dimensional simulation of protein (top) and its associated graph view (bottom) which indicating the average ratio of expression for spot 454 by using computational analysis with DeCyder 6.5 software.](jcav07p0367g001){#F1}

![Spot 454 was identified as hypoxia up-regulated 1 precursor (HYOU1) by using matrix-assisted laser desorption/ionization time of flight (MADLI-TOF/TOF), respectively. A) The peptide mass fingerprinting and LIFT analysis of spot 454, which was carried out using MADLI-TOF/TOF. B) Spot 454 was identified as HYOU1 through using Mascot search.](jcav07p0367g002){#F2}

![The expression of HYOU1 proteins in NPC. A) Detection the expression of HYOU1 in 5-8F cell line over-expressed LPLUNC1 and its control cell lines by qRT-PCR and Western Blot. Compared with control, \*\*P \< 0.01. B) Detection the expression of HYOU1 in HNE2 cell line over-expressed LPLUNC1 and its control cell lines by qRT-PCR and Western Blot. Compared with control, \*\*P \< 0.01. C) Detection the expression of HYOU1 in HONE1 cell line over-expressed LPLUNC1 and its control cell lines by qRT-PCR and Western Blot. Compared with control, \*\*P \< 0.01.](jcav07p0367g003){#F3}

![The expression of HYOU1 in nasopharyngeal carcinoma tissues. A) The expression of HYOU1 in normal tissues and nasopharyngeal carcinoma tissues by IHC detection (magnification×400, scale bars 20 µm). B) qRT-PCR analysis of the relative expression levels of HYOU1 in 36 NPC specimens and 15 NPE specimens; data were normalised according to β-actin. Differences between groups were analysed using the chisquare test (HYOU1: P = 0.001).](jcav07p0367g004){#F4}

![Expression levels of HYOU1 were significantly correlated with the survival of NPC patients. Kaplan-Meier estimated progression-free survival (PFS) and overall survival (OS) for NPC patients according to the expression levels of HYOU1 protein in 81 NPC patients. P values were obtained by using the log-rank test. N, The number of cases; Events, the number of cases, who had recurrent tumor or died during the follow-up period. P values were obtained by using the log-rank test. N, The number of cases; Events, the number of cases, who had recurrent tumor or died during the follow-up period.](jcav07p0367g005){#F5}

###### 

The clinicopathologic characteristics of specimens.

  Specimens                      Cases
  ------------------------------ -------
  NPE                            131
  Age (median 46.1 years) ≤ 48   66
  \> 48                          65
  Gender: male                   95
  female                         36
  NPC                            256
  Age (median 48.4 years) ≤ 48   125
  \> 48                          131
  Gender: male                   200
  female                         56
  Metastasis                     164
  No metastasis                  92
  Stages I                       28
  Stages II                      87
  Stages III                     89
  Stages IV                      52

NPE: non-tumor nasopharyngeal epithelium; NPC: nasopharyngeal carcinoma.

###### 

The different proteins identified by MALDI-TOF/TOF-MS/MS.

  Master No.   Accession number   Protein name                                                                                                                             T-test    Av. Ratio   Mass weight   pI      Coverage (%)   Scores
  ------------ ------------------ ---------------------------------------------------------------------------------------------------------------------------------------- --------- ----------- ------------- ------- -------------- --------
  1758         gi\|27807361       nuclease sensitive element binding protein 1                                                                                             0.0062    -3.19       35903         9.87    46             123
  1714         gi\|48145673       HNRPH1                                                                                                                                   0.023     -2.54       49384         5.79    42             153
  1744         gi\|27807361       nuclease sensitive element binding protein 1                                                                                             0.013     -2.5        35903         9.87    53             177
  1770         gi\|119581154      keratin 17, isoform CRA_a                                                                                                                0.014     -2.34       48232         5       53             252
  1771         gi\|4557701        keratin 17                                                                                                                               0.012     -2.3        48361         4.97    65             323
  1764         gi\|47939651       KRT17 protein                                                                                                                            0.016     -2.18       40520         4.9     41             87
  2857         gi\|337518         ribosomal protein                                                                                                                        0.01      -2.18       21835         10.09   48             78
  1558         gi\|62913980       KRT8 protein                                                                                                                             0.029     -1.84       41083         4.94    54             240
  497          gi\|5032179        Tripartite motif-containing 28                                                                                                           0.018     -1.68       90261         5.52    34             235
  2363         gi\|11056044       pyrophosphatase 1                                                                                                                        0.015     -1.61       33095         5.54    36             106
  1613         gi\|4504919        keratin 8                                                                                                                                0.00024   -1.54       53671         5.52    73             535
  2044         gi\|62738363       Chain A, The 2.1 A Structure Of A Tumour Suppressing Serpin                                                                              0.011     -1.49       42259         5.72    35             127
  1980         gi\|3646128        thioredoxin-like protein                                                                                                                 0.0056    -1.47       37751         5.25    54             165
  2806         gi\|4507669        tumor protein, translationally-controlled 1                                                                                              0.041     -1.44       19697         4.84    38             76
  2045         gi\|55597035       PREDICTED: gelsolin-like capping protein isoform 9                                                                                       0.022     -1.36       38779         5.88    47             188
  1257         gi\|62897681       calreticulin precursor variant                                                                                                           0.0033    -1.33       47061         4.3     20             66
  2115         gi\|157834561      Chain A, Aldehyde Reductase                                                                                                              0.036     -1.32       36761         6.34    36             80
  1760         gi\|4557701        keratin 17                                                                                                                               0.04      -1.3        48361         4.97    49             323
  1982         gi\|119575505      serpin peptidase inhibitor, clade B (ovalbumin), member 6, isoform CRA_c                                                                 0.0042    -1.29       44313         5.32    48             133
  1991         gi\|6678271        TAR DNA binding protein                                                                                                                  0.029     -1.26       45053         5.85    36             118
  1093         gi\|6470150        BiP protein                                                                                                                              0.041     -1.26       71002         5.23    18             71
  1525         gi\|66361514       Chain A, X-Ray Structure Of A Deletion Variant Of Human Glucose 6- Phosphate Dehydrogenase Complexed With Structural And Coenzyme Nadp   0.0066    -1.22       56688         6.69    43             187
  2493         gi\|112696539      immunoglobulin heavy chain variable region                                                                                               0.03      -1.22       11149         8.91    64             88
  2513         gi\|83754467       Chain A, Molecular Basis For The Recognition Of Phosphorylated And Phosphoacetylated Histone H3 By 14-3-3                                0.035     -1.21       29413         4.97    53             200
  454          gi\|5453832        hypoxia up-regulated 1 precursor                                                                                                         0.00067   -1.2        111494        5.16    17             173
  2011         gi\|48257132       GLRX3 protein                                                                                                                            0.036     1.2         32823         5.36    49             131
  1135         gi\|5729877        heat shock 70kDa protein 8 isoform 1                                                                                                     0.033     1.21        71082         5.37    54             251
  1383         gi\|67464392       Chain A, Structure Of Human Muscle Pyruvate Kinase                                                                                       0.0049    1.21        60277         8.22    36             73
  2265         gi\|190281         protein phosphatase I alpha subunit (PPPIA) (EC 3.1.3.16)                                                                                0.0034    1.22        35844         6.36    31             76
  2577         gi\|4505773        prohibitin                                                                                                                               0.014     1.22        29843         5.57    58             205
  1495         gi\|220702506      Chain A, TapasinERP57 HETERODIMER                                                                                                        0.017     1.23        54541         5.61    60             262
  1091         gi\|24234688       heat shock 70kDa protein 9 precursor (HSPA9 )                                                                                            0.045     1.25        73920         5.87    37             351
  2264         gi\|109102505      PREDICTED: similar to Serine/threonine-protein phosphatase PP1-beta catalytic subunit (PP-1B) isoform 1                                  0.021     1.25        34840         5.83    19             175
  1130         gi\|167466173      heat shock 70kDa protein 1B                                                                                                              0.036     1.26        70294         5.48    46             187
  1486         gi\|23308577       phosphoglycerate dehydrogenase                                                                                                           0.0063    1.26        57356         6.29    41             237
  2261         gi\|31645          glyceraldehyde-3-phosphate dehydrogenase                                                                                                 0.013     1.33        36202         8.26    8              97
  2559         gi\|5454052        stratifin                                                                                                                                0.021     1.34        27871         4.68    60             202
  1755         gi\|5031573        ARP3 actin-related protein 3 homolog                                                                                                     0.044     1.37        47797         5.61    31             80
  2337         gi\|4502101        annexin I                                                                                                                                0.048     1.38        38918         6.57    40             100
  1940         gi\|4757756        annexin A2 isoform 2                                                                                                                     0.004     1.4         38808         7.57    37             106
  2211         gi\|119602552      hCG2036836                                                                                                                               0.013     1.52        13613         8.63    56             71
  1424         gi\|151567677      Chain A, X-Ray Structure Of Human Thioredoxin Reductase 1                                                                                0.0037    1.55        57632         6.48    35             131
  1431         gi\|49168498       TXNRD1                                                                                                                                   0.017     1.67        55281         6.07    32             95
  2151         gi\|4557976        Chain A, Human Muscle Fructose 1,6-Bisphosphate Aldolase Complexed With Fructose 1,6-Bisphosphate                                        0.002     1.95        39720         8.39    48             158

###### 

Relationships between HYOU1 expression level and clinicopathologic characteristics.

  Characteristics   cases   HYOU1         
  ----------------- ------- ------- ----- -------
  Normal            131     23      108   
  Age ≤ 48          66      12      54    
  \> 48             65      11      54    0.850
  Gender: male      95      17      78    
  Female            36      6       30    0.869
  Tumor             256     171     85    
  Age ≤ 48          125     87      38    
  \> 48             131     84      47    0.583
  Gender: male      200     131     69    
  Female            56      40      16    0.405
  Metastasis        164     127     37    
  No metastasis     92      44      48    0.000
  Stages I + II     115     66      49    
  Stages III + IV   141     105     36    0.004

###### 

Cox regression analyses of the various factors associated with PFS and OS in NPC patients.

  ---------------------------------------------------------------------------------------------------------------
  Variables                  progression-free survival   overall survival                                 
  -------------------------- --------------------------- ------------------ ------- ------- ------------- -------
  Gender (Female/Male)       0.539                       0.229-1.270        0.157   0.516   0.215-1.237   0.138

  Age (≤ 48/\> 48)           0.748                       0.396-1.414        0.372   0.672   0.354-1.276   0.224

  Stage (I + II/ III + IV)   2.028                       0.684-6.015        0.202   2.289   0.815-6.430   0.116

  Metastasis\                0.427                       0.138-1.323        0.140   0.438   0.152-1.262   0.126
  No metastasis                                                                                           

  HYOU1 (High/Low)           2.602                       1.295-5.225        0.007   2.507   1.251-5.022   0.010
  ---------------------------------------------------------------------------------------------------------------

Note: HR, hazard ratio; 95% CI, 95% confidence interval.
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